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Regions on chromosomes 7 and 19 were recently reported to contain susceptibility loci that regulate tumor ag-
gressiveness of prostate cancer. To confirm these findings, we analyzed genome scan data from 161 pedigrees
affected with prostate cancer. Using the Gleason score as a quantitative measure of tumor aggressiveness, we
regressed the squared trait difference, as well as the mean-corrected cross product, on the estimated proportion of
alleles shared identical-by-descent at each marker position. Our results confirm the previous linkage results for
chromosome 19q (D19S902, ). In addition, we report suggestive evidence for linkage on chromosomeP ! .00001
4 (D4S403, ). The results of previous findings, together with our results, provide strong evidence thatPp .00012
chromosome 19 harbors a gene for tumor aggressiveness.
Prostate cancer (MIM 176807) is the most common type
of cancer and the second leading cause of cancer death
among men in the United States. Substantial evidence
has shown that it clusters in families (Steinberg et al. 1990;
Goldgar et al. 1994; Whittemore et al. 1995), with a two-
to fourfold increased risk of disease for first-degree rel-
atives of an affected man. Furthermore, this clustering
can partially be attributed to genetic causes (Ahlbom et
al. 1997; Schaid et al. 1998). As a result, research efforts
have focused on mapping the susceptibility genes(s) us-
ing linkage analysis methods (Smith et al. 1996; Berthon
et al. 1998; Xu et al. 1998, 2001; Gibbs et al. 1999,
2000; Berry et al. 2000; Tavtigian et al. 2001). Recently,
an analysis was conducted by Witte et al. (2000), in
which they used the total Gleason score as a quantitative
trait. The Gleason score is a cancer grading system that
is based on the architectural pattern of biopsy or pros-
tatectomy specimens. It is obtained by adding two his-
tological pattern grades, each of which is individually
scored from 1 to 5. The total Gleason score thus ranges
from2 to 10, with a high score generally indicatinghigher-
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grade disease associated with poor prognosis (Epstein et
al. 1993; Lerner et al. 1996).
Witte et al. (2000) used the Gleason score as a quan-
titative trait to search for genes related to tumor ag-
gressiveness. They conducted a genomewide scan using
a total of 236 sib pairs. Strong evidence for linkage was
found on 5q31 ( ), 7q32-q34 ( ), andPp .0002 Pp .0007
19q12 ( ). However, in follow-up analyses,Pp .0004
only the findings on chromosomes 7 and 19 were main-
tained (Neville et al. 2002).
To confirm the findings of Witte et al. (2000), we
analyzed our genome scan data of families with prostate
cancer, using the Gleason score as a quantitative trait.
These families with prostate cancer were identified from
surveys of men treated by radical prostatectomy or ra-
diation therapy at the Mayo Clinic between 1967 and
1997. A pedigree was ascertained if it had a minimum
of three closely related men affected with prostate cancer
and if at least two of the affected men were willing to
give blood. All affected men who contributed a blood
specimen had their cancers verified by review of medical
records and pathologic confirmation (see Schaid et al.
[1998] and Berry et al. [2000]). A total of 161 families
were ascertained. These families consisted of 448 men
affected with prostate cancer; Gleason scores were avail-
able on 364 of the men. The scores were obtained from
either radical prostatectomy specimens, or, if no speci-
mens were available, the score was obtained from six
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core needle biopsies. Collection of blood and family his-
tory data was approved by the Mayo Clinic Internal
Review Board.
For the genomewide screen, 400markers from theABI
Prism Linkage Mapping Set 10cM were used. Forward
primers were labeled with phosphoramidite dyes. Each
15ml reaction contained 25ng of genomic DNA, 200 mM
dNTPs, 0.33 mM each primer, 0.5 U AmpliTaqGold (PE
Biosystems), and 1.5–2.5 mM MgCl2. Reactions were
cycled in either a Perkin Elmer 9600 GeneAmp PCR
System or a MJR Tetrad Cycler, as follows: 10 min at
95C; 35 cycles of 30 s at 95C, 30 s at 58C or 55C,
and 30 s at 72C; and then a final 10-min extension at
72C. Reactions were held at 5C until analysis. PCR
products were resolved on 5%denaturing polyacrylamide
gels using an ABI 377 DNA sequencer. Genotypes were
analyzed using ABI Genescan 2.1 and ABI Genotypes
2.0 and 2.5 software packages. Through the use of SAS
and Splus programs, we checked for Mendelian errors,
mislabeling of marker names, out-of-range alleles, and
Hardy-Weinberg equilibrium. We also used the program
RELPAIR (Boehnke and Cox 1997) to confirm familial
relationships.
Similar to Witte et al. (2000), we used the Haseman-
Elston (HE) method of quantitative-trait linkage analysis
(Elston et al. 2000; S.A.G.E. 2002). This method regresses
either the trait-difference-squared (original HE) or the
trait-mean-corrected-product (revised HE) on the esti-
mated proportion of alleles shared identical-by-descent
(IBD) at each marker locus. The sample mean Gleason
score was used for the revised HE function. For multiple
brother-pairs from the same family, their nonindepend-
ence is corrected in the analysis through the use of
weighted least squares (Elston et al. 2000). We usedmul-
tipoint estimates of IBD sharing to achieve the most
accurate IBD probability estimates, and we regressed the
trait on each marker position (as opposed to simulta-
neously modeling multiple markers). For the chromo-
some X analysis, we used ordinary least squares, assum-
ing all brother-pairs are independent, to model either the
original HE or the revised HE on the IBD-sharing prob-
abilities. The IBD information was generated in MER-
LIN (Abecasis et al. 2002).
A total of 197 affected brother pairs were available for
genetic analysis. The mean Gleason score is 5.68 (range
2–10). The distribution of scores are: Gleason 2 (4.9%),
Gleason 3 (2.5%), Gleason 4 (6.3%), Gleason 5 (33.8%),
Gleason 6 (22.8%), Gleason 7 (21.7%), Gleason 8
(4.7%), Gleason 9 (3.0%), and Gleason 10 (0.3%).
Singlepoint linkage results from the genome screen are
presented in figure 1. The vertical axis of each plot is
log(P), where P is the P value from each of the two
HE analyses. Following the criteria for declaring signif-
icance (Lander and Kruglyak 1995), chromosome19q13
shows significant evidence for linkage on the basis of the
original HE analysis. The highest peak occurs at marker
D19S902 ( ). The span of this region withinP ! .0001
which is∼6.5 cM in length.Of great importance,P ! .001
this region is near the region showing evidence for link-
age by Witte et al. (2000). With the use of the revised
HE approach, the authors report evidence for linkage
) at marker D19S433. The distance between(Pp .0004
the markers D19S433 and D19S902 is ∼20 cM, on the
basis of the Marshfield map. To our knowledge, our
finding is the first replication, using independent data,
of the positive linkage findings of Witte et al. (2000).
This is an extraordinary finding, because replication
of results from gene-mapping studies of complex dis-
eases is difficult (Vieland 2001), particularly for prostate
cancer (Ostrander and Stanford 2000).
We also observed suggestive evidence for linkage on
chromosomes 4 and 15q (fig. 1), on the basis of the orig-
inal HE approach. The peak on chromosome 4 occurs
at marker D4S403 ( ), a region not identifiedPp .00012
by Witte et al. (2000). However, two other genomewide
screens have reported linkage between this marker and
prostate cancer. Smith et al. (1996) reported a two-point
LOD score of ∼1.6, and Goddard et al. (2001) reported
a LOD score of 1.80, after adjusting for age at onset in
the analysis. The region on chromosome 15q23 was lo-
cated at marker D15S131 ( ). This region wasPp .0014
not identified by Witte et al. (2000) nor by other groups.
For the other linked regions on chromosomes 5 and 7
that were identified by Witte et al. (2000), we observed
an elevated peak on only chromosome 5q31, located in
the same region but not as significant ( ) as thatPp .005
observed by Witte et al. (2000). However, the results for
this region are still unclear, since, in a follow-up analysis,
members of the Witte et al. (2000) group reported that
the LOD scores diminished on 5q31 (Neville et al. 2002).
Our findings tended to show the squared-trait-differ-
ence to be more significant than the cross product (the
opposite of the results of Witte et al. [2000]). There are
four possible explanations for this. First, theoretical cal-
culations for large sample sizes indicate that the squared-
trait-difference has greater power than the cross product
when the sibling correlation is 10.27 (Visscher and Hop-
per 2001). In our data, the sibling correlation of Gleason
score was 0.22. It may be that, in our data, the corre-
lation is bordering the threshold for which the squared-
trait-difference achieves greater power. Second, as-
certainment may also have a role here. Under strong
ascertainment, the trait difference has been shown, via
simulations, to have greater power than the cross prod-
uct (Palmer et al. 2000). Our pedigrees were ascertained
on the basis of a list of index cases who were treated at
the Mayo Clinic. These individuals may have a more
severe form of prostate cancer, and, as a result, they may
have shifted the distribution of Gleason scores toward
higher scores. However, the distribution of Gleason
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Figure 1 Linkage scan for loci segregating with prostate tumor aggressiveness. The solid line denotes the original HE analysis (i.e., the
trait-difference-squared); the broken dotted/dashed line denotes the revised HE analysis (i.e., trait-mean-corrected product). The horizontal
dotted/dashed line in each subfigure indicates where ( ). Points above this line denote . Tick marks on the X-Pp .001  log [P]p 3 P ! .001
axis denote marker locations.
scores for Mayo prostate cancer cases is comparable to
that of Witte et al. (2000). Moreover, owing to PSA
screening, the Gleason scores might be attenuated be-
cause prostate cancer is detected earlier. Thus, the effect
of ascertainment is not likely to be a major influence.
Third, the power of the cross product is reduced when
the mean used in the calculations deviates from the true
population mean (Palmer et al. 2000). We used the sam-
ple mean in our analysis of the cross product; however,
we tried other prespecified values to explore the sensi-
tivity of our results on chromosome 19. The significance
level of the cross product varied across the values of the
mean, but none reached the significance level of the dif-
ference-squared (results not shown). Finally, random
chance might explain the greater significance with the
squared-trait difference.
Nineteen percent of our cases (or 84 individuals) were
missing Gleason scores. This missing data will have very
little effect on our results, because 78 of these cases were
affected fathers who had no affected brothers and, hence,
would not have entered into the analysis.
In summary, we report strong evidence for linkage on
chromosome 19q13 and suggestive evidence on chromo-
some 4q. Our finding on chromosome 19, together with
previous findings of Witte et al. (2000), strongly suggests
that susceptibility loci exist for tumor aggressiveness,
and, since we found this locus with the trait-difference-
squared outcome, which is a similarity score, this finding
suggests that the putative locus may have alleles that not
only promote more aggressive tumors, but also lead to
less aggressive disease.
Acknowledgments
This work was supported by National Cancer Institute
grants CA 94919 and CA 72818.
762 Am. J. Hum. Genet. 72:759–762, 2003
Electronic-Database Information
Accession number and URL for data presented herein are as
follows:
Online Mendelian Inheritance in Man (OMIM), http://www
.ncbi.nlm.nih.gov/Omim/ (for prostate cancer [MIM
176807])
References
Abecasis GR, Cherny SS, Cookson WO, Cardon LR (2002)
Merlin: rapid analysis of dense genetic maps using sparse
gene flow trees. Nat Genet 30:97–101
Ahlbom A, Lichtenstein P, Malmstrom H, Feychting M, Hem-
minki K, Pedersen NL (1997) Cancer in twins: genetic and
nongenetic familial risk factors. J Natl Cancer Inst 89:287–
293
Berry R, Schroeder JJ, French AJ, McDonnell SK, Peterson BJ,
Cunningham JM, Thibodeau SN, Schaid DJ (2000) Evidence
for a prostate cancer-susceptibility locus on chromosome 20.
Am J Hum Genet 67:82–91
Berthon P, Valeri A, Cohen-Akenine A, Drelon E, Paiss T,Wohr
G, Latil A, et al (1998) Predisposing gene for early-onset
prostate cancer, localized on chromosome 1q42.2-43. Am J
Hum Genet 62:1416–1424
BoehnkeM, Cox NJ (1997) Accurate inference of relationships
in sib-pair linkage studies. Am J Hum Genet 61:423–429
Elston RC, Buxbaum S, Jacobs KB, Olson JM (2000) Hasemen
and Elston revisited. Genet Epidemiol 19:1–17
Epstein JI, Carmichael M, Partin AW, Walsh PC (1993) Is
tumor volume an independent predictor of progression fol-
lowing radical prostatectomy? A multivariate analysis of
185 clinical stage B adenocarcinomas of the prostate with
5 years of followup. J Urol 149:1478–1781
Gibbs M, Chakrabarti L, Stanford JL, Goode EL, Kolb S,
Schuster EF, Buckley VA, Shook M, Hood L, Jarvik GP,
Ostrander EA (1999) Analysis of chromosome 1q42.2–43
in 152 families with high risk of prostate cancer. Am J Hum
Genet 64:1087–1095
Gibbs M, Stanford JL, Jarvik GP, Janer M, Badzioch M, Peters
MA, Goode EL, Kolb S, Chakrabarti L, Shook M, Basom
R, Ostrander EA, Hood L (2000) A genomic scan of families
with prostate cancer identifies multiple regions of interest.
Am J Hum Genet 67:100–109
Goddard KA, Witte JS, Suarez BK, Catalona WJ, Olson JM
(2001) Model-free linkage analysis with covariates confirms
linkage of prostate cancer to chromosomes 1 and 4. Am J
Hum Genet 68:1197–1206
Goldgar D, Easton D, Cannon-Albright L, Skolnick M (1994)
Systematic population-based assessment of cancer risk in
first-degree relatives of cancer probands. J Natl Cancer Inst
86:1600–1608
Lander E, Kruglyak L (1995) Genetic dissection of complex
traits: guidelines for interpreting and reporting linkage re-
sults. Nat Genet 11:241–247
Lerner SE, Blute ML, Bergstralh EJ, Bostwick DG, Eickholt
JT, Zincke H (1996) Analysis of risk factors for progression
in patients with pathologically confined prostate cancers af-
ter radical retropubic prostatectomy. J Urol 156:137–143
Neville PJ, Conti DV, Goddard KA, Krumroy LM, Catalona
WJ, Witte JS, Casey G (2002) Further characterization of
prostate cancer aggressiveness loci. Proc Annu Meet Am
Assoc Cancer Res 23:3131
Ostrander EA, Stanford JL (2000) Genetics of prostate cancer:
toomany loci, too few genes. Am JHumGenet 67:1367–1375
Palmer LJ, Jacobs KB, Elston RC (2000) Haseman and Elston
revisited: the effects of ascertainment and residual familial
correlations on power to detect linkage. Genet Epidemiol
19:456–460
S.A.G.E. (2002) Statistical analysis for genetic epidemiology.
Statistical Solutions, Cork, Ireland
Schaid D, McDonnell SK, Blute ML, Thibodeau S (1998) Ev-
idence for autosomal dominant inheritance of prostate can-
cer. Am J Hum Genet 62:1425–1438
Smith JR, Freije D, Carpten JD, Gronberg H, Xu J, Isaacs SD,
Brownstein MJ, Bova GS, Guo H, Bujnovszky P, Nusskern
DR, Damber JE, Bergh A, Emanuelsson M, Kallioniemi OP,
Walker-Daniels J, Bailey-Wilson JE, Beaty TH, Meyers DA,
Walsh PC, Collins FS, Trent JM, Isaacs WB (1996) Major
susceptibility locus for prostate cancer on chromosome 1
suggested by a genome-wide search. Science 274:1371–1374
Steinberg G, Carter B, Beaty T, Childs B, Walsh P (1990) Family
history and the risk of prostate cancer. Prostate 17:337–347
Tavtigian SV, Simard J, Teng DH, Abtin V, Baumgard M, Beck
A, Camp NJ, et al (2001) A candidate prostate cancer sus-
ceptibility gene at chromosome 17p. Nat Genet 27:172–180
Vieland VJ (2001) The replication requirement. Nat Genet 29:
244–245
Visscher PM, Hopper JL (2001) Power of regression and max-
imum likelihood methods to map QTL from sib-pair and
DZ twin data. Ann Hum Genet 65:583–601
Whittemore AS, Wu A, Kolonel L, John E, Gallagher R, Howe
G, West D, Teh C, Stamey T (1995) Family history and
prostate cancer risk in black, white, and Asian men in the
United States and Canada. Am J Epidemiol 141:732–740
Witte JS, Goddard KA, Conti DV, Elston RC, Lin J, Suarez
BK, Broman KW, Burmester JK, Weber JL, Catalona WJ
(2000) Genomewide scan for prostate cancer-aggressiveness
loci. Am J Hum Genet 67:92–99
Xu J, Meyers D, Freije D, Isaacs S, Wiley K, Nusskern D,
Ewing C, et al (1998) Evidence for a prostate cancer sus-
ceptibility locus on the X chromosome. Nat Genet 20:175–
179
Xu J, Zheng SL, Hawkins GA, Faith DA, Kelly B, Isaacs SD,
Wiley KE, Chang B, Ewing CM, Bujnovszky P, Carpten JD,
Bleecker ER, Walsh PC, Trent JM, Meyers DA, Isaacs WB
(2001) Linkage and association studies of prostate cancer
susceptibility: evidence for linkage at 8p22-23. Am J Hum
Genet 69:341–350
